Theinfluenzavaccinefieldhasbeenconstantlyevolvingtoimprovethespeed,scalability,andflexibilityofmanufacturing,andto
improvethebreadthandlongevityoftheprotectiveimmuneresponseacrossagegroups,givingrisetoanarrayofnextgeneration
vaccinesindevelopment.Amongthese,therecombinantinfluenzavaccinetetravalent(RIV4),usingabaculovirusexpressionvector
systemtoexpressrecombinanthaemagglutinin(r HA)ininsectcells, istheonlyonetohavereachedthemarketandhasbeen
studiedextensively. Wedescribehowtheuniquestructuralfeaturesofr HAin RIV4improveprotectiveimmuneresponsescompared
toconventionalinfluenzavaccinesmadefrompropagatedinfluenzavirus.Inadditiontothesequenceintegrity,characteristicof
recombinantproteins, uniquepost-translationalprocessingofther HAininsectcellsinstillsfavourabletertiaryandquaternary
structuralfeatures. Theabsenceofprotease-drivencleavageandadditionofsimple N-linkedglycanshelptopreserveandexpose
certainconservedepitopeson HAmolecules, whicharelikelyresponsibleforthehighlevelsofbroadlycross-reactiveandprotective
antibodieswithrarespecificitiesobservedwith RIV4. Furthermore, thepresenceofuniformcompact HAoligomersandabsenceof
eggproteins, viral RNAorprocessimpurities, typicallyfoundinconventionalvaccines, areexpectedtoeliminatepotentialadverse
reactionstothesecomponentsinsusceptibleindividualswiththeuseof RIV4. Thesedistinctstructuralfeaturesandpurityofthe
recombinant HAvaccinethusprovideanumberofbenefitsinvaccineperformancewhichcanbeextendedtootherviraltargets,
suchasfor COVID-19.